Truist Lifts PT on Costco Wholesale Corporation (COST) to $977 From $926 - Here's Why
Costco Wholesale Corporation (NASDAQ:COST) is one of the best stocks that will always grow.
On March 6, Truist lifted the price target on Costco Wholesale Corporation (NASDAQ:COST) to $977 from $926, reiterating a Hold rating on the shares and telling investors that while the company posted another solid quarter, its membership growth remains a headwind. The firm further stated in a research note that the stock’s valuation does not leave a lot of room for error, and investors want to see member growth inflect for the stock’s multiple to re-expand.
The same day, BMO Capital also lifted the price target on Costco Wholesale Corporation (NASDAQ:COST) to $1,315 from $1,175 while maintaining an Outperform rating on the shares. The rating update came after the company’s earnings release, with the firm telling investors that the stock should remain a core holding.
Costco Wholesale Corporation (NASDAQ:COST) announced fiscal Q2 and year-to-date operating results for fiscal 2026 on March 5, reporting that net sales for the quarter rose 9.1% to $68.24 billion from $62.53 billion last year. Net sales for the first 24 weeks experienced an 8.7% growth, reaching $134.22 billion compared to $123.52 billion last year.
Costco Wholesale Corporation (NASDAQ:COST) operates membership-only big box warehouse club stores and is one of the most popular department stores in the US. It offers its customers elaborate offerings, including food, beverages, groceries, and more.
While we acknowledge the potential of COST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cullinan Therapeutics: Fourth Quarter Earnings Overview
Tenax Therapeutics: Fourth Quarter Earnings Overview
Ripple Executive Says XRP May Become the ‘Glue’ of Blockchain Finance
